Highly selective inhibitors of adams activity
The invention concerns the development of appropriately designed and synthesized chemical entities that selectively exert their activity on ADAMs, A Disintegrin And Metalloproteinase (ADAM) enzyme.
Tongue muscle rehabilitation device
The invention consists of a novel experimental set-up for the muscular rehabilitation of the tongue, which is necessary for the restoration of motility and physiological function of the organ for the purpose of adequate swallowing in patients, who are post-stroke or otherwise have impaired tongue motility.
Method implemented by means of a computer for determining retention times and concentration values of analytes in a mixture
The present invention relates to the automation of data interpretation from a chromatography analysis, such specifically the retention times and concentration values of analytes in a mixture.
Isoindoline derivatives such as AMPK activators
The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity, as well as immune-mediated inflammatory diseases and cancer.
Benzofuran derivatives as AMPK activators
The present invention relates to the development of novel benzofuran derivatives able to activate AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in the regulation of immune homeostasis
BENZO[D]ISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE core derivatives and their use in the treatment of cancer
The present invention relates to novel benzo[d]isothiazolic-3(2H)-one-1,1-dioxide core compounds able to effectively and selectively inhibiting the IX and XII isoforms of the enzyme carbonic anhydrase (CA), which are predominantly expressed in hypoxic and metastatic tumors.
Compounds for use in the therapeutic and preventive treatment of neurodegenerative diseases, particularly Alzheimer’s disease
The object of the present invention is the design, synthesis, and pharmacological evaluation of novel diphenylmethane core molecules, capable of simultaneously promoting activation of the autophagy process and lipid catabolism, both in vitro and in vivo. Their dual activity may represent a novel approach for the treatment of neurodegenerative diseases, such as Alzheimer.
Compounds with a Benzo[a]carbazole structure and their uses
The present invention concerns the development of new derivatives with apoptosis-modulating action by inhibition of the MDM2/p53 complex.
Synthetic analogues of xanthohumol
The present invention relates to new synthetic analogs of Xanthohumol (XN), a naturally occurring prenylated chalcone found in the female inflorescence of the hop plant (Humulus lupulus L. - Cannabaceae). Xanthohumol is a flavonoid known for its multiple properties
Synthetic analogues of 3-iodothyronamine (T1AM) and uses thereof
The invention aims to the development of new synthetic analogs of 3-iodothyronamine (T1AM), an exponent of a class of endogenous molecules derived from thyroid hormones. The possible main therapeutic uses are: treatment of obesity and dyslipidemia,neuro-psychiatric and behavioral disorders,neurodegenerative diseases.